Agile Drug Patent Portfolio
Agile owns 1 orange book drug protected by 8 US patents Given below is the list of Agile's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8246978 | Dermal delivery device with reduced loss of its volatile components | 26 Aug, 2028 | Active |
US8747888 | Dermal delivery device with in situ seal | 10 Jul, 2028 | Active |
US9050348 | Dermal delivery device | 10 Jul, 2028 | Active |
US7045145 | Transdermal contraceptive delivery system and process | 14 Mar, 2021 | Expired |
US7384650 | Skin permeation enhancement composition for transdermal hormone delivery system | 14 Mar, 2021 | Expired |
US8221784 | Transdermal hormone delivery system: compositions and methods | 14 Mar, 2021 | Expired |
US8221785 | Transdermal hormone delivery system: compositions and methods | 14 Mar, 2021 | Expired |
US8883196 | Transdermal hormone delivery system: compositions and methods | 22 Nov, 2020 | Expired |
Latest Legal Activities on Agile's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Agile.
Activity | Date | Patent Number |
---|---|---|
Maintenance Fee Reminder Mailed
Critical
| 04 Mar, 2024 | US8221784 |
Maintenance Fee Reminder Mailed
Critical
| 04 Mar, 2024 | US8221785 |
Payment of Maintenance Fee, 12th Yr, Small Entity | 21 Feb, 2024 | US8246978 |
Expire Patent
Critical
| 19 Dec, 2022 | US8883196 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 09 Dec, 2022 | US9050348 |
Maintenance Fee Reminder Mailed
Critical
| 04 Jul, 2022 | US8883196 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 21 Feb, 2020 | US8246978 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 17 Jan, 2020 | US8221784 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 17 Jan, 2020 | US8221785 |
Payment of Maintenance Fee, 12th Yr, Small Entity | 10 Dec, 2019 | US7384650 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 10 Dec, 2018 | US9050348 |
Payment of Maintenance Fee, 4th Yr, Small Entity | 11 May, 2018 | US8883196 |
Payment of Maintenance Fee, 12th Yr, Small Entity | 16 Nov, 2017 | US7045145 |
Application ready for PDX access by participating foreign offices
Critical
| 31 Aug, 2015 | US8883196 |
Patent Issue Date Used in PTA Calculation
Critical
| 09 Jun, 2015 | US9050348 |
Agile's Family Patents
Agile drugs have patent protection in a total of 12 countries. It has a significant patent presence in the US with 53.6% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Agile Drug List
Given below is the complete list of Agile's drugs and the patents protecting them.
1. Twirla
Twirla is protected by 8 patents, out of which 5 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8246978 | Dermal delivery device with reduced loss of its volatile components |
26 Aug, 2028
(3 years from now)
| Active |
US8747888 | Dermal delivery device with in situ seal |
10 Jul, 2028
(3 years from now)
| Active |
US9050348 | Dermal delivery device |
10 Jul, 2028
(3 years from now)
| Active |
US7045145 | Transdermal contraceptive delivery system and process |
14 Mar, 2021
(3 years ago)
| Expired |
US7384650 | Skin permeation enhancement composition for transdermal hormone delivery system |
14 Mar, 2021
(3 years ago)
| Expired |
US8221784 | Transdermal hormone delivery system: compositions and methods |
14 Mar, 2021
(3 years ago)
| Expired |
US8221785 | Transdermal hormone delivery system: compositions and methods |
14 Mar, 2021
(3 years ago)
| Expired |
US8883196 | Transdermal hormone delivery system: compositions and methods |
22 Nov, 2020
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twirla's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List